Dr Mohty on the Implications of Real-World Efficacy With Elranatamab in R/R Myeloma

Mohamad Mohty, MD, PhD, professor, hematology, Sorbonne University, head, Clinical Hematology and Cellular Therapy Department, Saint-Antoine Hospital, shares the rationale for investigating the real-world efficacy of elranatamab-bcmm (Elrexfio) in patients with relapsed/refractory multiple myeloma.

Mohty begins by stating there have been significant advancements in the treatment of patients with relapsed/refractory multiple myeloma, especially for those who are triple-exposed or triple-refractory. These patients have been treated with an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an IMiD, which makes their disease particularly challenging to manage when it relapses, he explains. Immunotherapies have emerged as a beacon of hope for this patient group, offering potential new avenues for treatment, according to Mohty. These therapies can be administered as either cellular therapies, such as CAR T cells, or bispecific antibodies, Mohty says. Selecting the right target for these therapies is essential, and BCMA has proven to be a highly effective target, he adds.

As a result, BCMA-directed therapies have been approved by regulatory agencies and are in clinical use, Mohty reports, adding that bispecific antibodies targeting BCMA have also been approved. The approvals of these agents were based on the outcomes of single-arm clinical trials, which demonstrated their efficacy, feasibility, and safety profiles, he explains.

Although clinical trials provide crucial data for approval, it is equally important to gather information on the use of these therapies outside of the trial setting, Mohty elucidates. Real-world patients tend to have some of the most difficult multiple myeloma cases to treat, and studies evaluating these patients provide valuable insights into the real-world application of these therapies, he notes.

The study investigating the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma used data from the French compassionate use program, Mohty expands. The findings highlighted the importance of real-world data in understanding the effectiveness and safety of new treatments for patients with relapsed/refractory multiple myeloma, particularly those who have exhausted conventional treatment options, he says. By examining these real-world applications, oncologists can better assess the impact of innovative therapies and refine treatment strategies to improve patient outcomes, Mohty concludes.